Predictors of clinically significant quality of life impairment in Parkinson's disease

Predictors of clinically significant quality of life impairment in Parkinson's disease

Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Santos García, Diego, de Deus Fonticoba, Teresa, Cores Bartolomé, Carlos, Muñoz, G, Paz González, J. M, Martínez Miró, C, Suárez, E, Jesús, S, Aguilar Barberà, Miquel, Planellas, L, Cosgaya, Marina, García Caldentey, J, Caballol, Nuria, Hernández-Vara, Jorge, Cabo-Lopez, Iria, López Manzanares, L, Ávila, Asunción, Nogueira, V, Borrué, Carmen, Solano Vila, B, Vela, Lydia, Cubo, Esther, Carrillo Padilla, Francisco, Martínez-Castrillo, Juan Carlos, Sánchez Alonso, P, Alonso Losada, M. G, Gastón, I, Clavero, P, Blázquez Estrada, Marta, Seijo, M, Rúiz Martínez, J, Valero, C, Fàbregues-Boixar i Nebot, Oriol de, González-Ardura, J, Ordás, C, López Díaz, L. M, Martinez-Martin, P, Adarmes, D. A, Almeria, Marta, Alonso-Cánovas, Araceli, Alonso Frech, Fernando, Alonso Redondo, Rubén, Álvarez, I, Aneiros Díaz, Á, Arnáiz, S, Arribas, S, Ascunce Vidondo, A, Bernardo Lambrich, N, Bejr-Kasem Marco, Helena, Buongiorno, M. T, Carrillo, F, Casas, E, Cortina Fernández, A, Cots-Foraster, Anna, Crespo Cuevas, Ane Miren, Díez-Fairen, M, Dotor García-Soto, J, Erro, E, Gallego, Miguel, García Campos, C, García Moreno, José Manuel, González Aloy, J, González García, B, González Palmás, M. J, Guardia, G, Horta, Andrea, Infante, J, Labrador-Espinosa, Miguel A, Lage Castro, M, López Seoane, B, Lucas del Pozo, S, Macías, Y, Meitín, M. T, Menéndez González, M, Méndez del Barrio, C, Miranda Santiago, J, Casado, M, Novo Amado, A, Novo Ponte, S, Pagonabarraga Mora, Javier, Pareés, I, Pascual-Sedano, Berta María, Pérez Fuertes, A, Pérez Noguera, R, Prats, M. A, Prieto Jurczynska, C, Pueyo Morlans, M, Puig-Davi, Arnau, Redondo Rafales, N, Rodríguez Méndez, L, Rodríguez Pérez, A. B, Roldán, F, Sánchez Díez, G, Sánchez Rodríguez, A, Santacruz, P, Segundo Rodríguez, J. C, Tartari, J. P, Vargas, L, Vives-Pastor, B, Villar, M. D
Format: Artikel
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663-17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975-22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.